PL3341016T3 - Sposoby i kompozycje do ochrony immunologicznej przed pozajelitowymi patogennymi e. coli - Google Patents
Sposoby i kompozycje do ochrony immunologicznej przed pozajelitowymi patogennymi e. coliInfo
- Publication number
- PL3341016T3 PL3341016T3 PL16760616.9T PL16760616T PL3341016T3 PL 3341016 T3 PL3341016 T3 PL 3341016T3 PL 16760616 T PL16760616 T PL 16760616T PL 3341016 T3 PL3341016 T3 PL 3341016T3
- Authority
- PL
- Poland
- Prior art keywords
- coli
- compositions
- methods
- protection against
- immune protection
- Prior art date
Links
- 241000588724 Escherichia coli Species 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000001717 pathogenic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Polymers & Plastics (AREA)
- Materials Engineering (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562209091P | 2015-08-24 | 2015-08-24 | |
| US201562210655P | 2015-08-27 | 2015-08-27 | |
| PCT/US2016/048278 WO2017035181A1 (en) | 2015-08-24 | 2016-08-24 | Methods and compositions for immune protection against extra-intestinal pathogenic e. coli |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3341016T3 true PL3341016T3 (pl) | 2023-11-13 |
Family
ID=56855827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16760616.9T PL3341016T3 (pl) | 2015-08-24 | 2016-08-24 | Sposoby i kompozycje do ochrony immunologicznej przed pozajelitowymi patogennymi e. coli |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US10583185B2 (pl) |
| EP (2) | EP4245320A3 (pl) |
| JP (1) | JP6872532B2 (pl) |
| KR (1) | KR102735147B1 (pl) |
| CN (1) | CN108430500B (pl) |
| AU (1) | AU2016312422B2 (pl) |
| BR (1) | BR112018003469A2 (pl) |
| EA (1) | EA037500B1 (pl) |
| ES (1) | ES2951408T3 (pl) |
| HR (1) | HRP20230947T1 (pl) |
| HU (1) | HUE063961T2 (pl) |
| IL (1) | IL257608B (pl) |
| MX (1) | MX2018002340A (pl) |
| PL (1) | PL3341016T3 (pl) |
| RS (1) | RS64449B1 (pl) |
| SM (1) | SMT202300220T1 (pl) |
| TW (1) | TWI715617B (pl) |
| WO (1) | WO2017035181A1 (pl) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2351578T (lt) * | 2005-06-27 | 2017-04-10 | Glaxosmithkline Biologicals S.A. | Vakcinų gavimo būdas |
| PT2945651T (pt) | 2013-01-17 | 2018-06-12 | Arsanis Biosciences Gmbh | Anticorpo específico para mdr e. coli |
| AU2015220723C1 (en) | 2014-02-24 | 2018-04-05 | Glaxosmithkline Biologicals Sa | Novel polysaccharide and uses thereof |
| TWI715617B (zh) | 2015-08-24 | 2021-01-11 | 比利時商葛蘭素史密斯克藍生物品公司 | 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物 |
| AR109621A1 (es) | 2016-10-24 | 2018-12-26 | Janssen Pharmaceuticals Inc | Formulaciones de vacunas contra glucoconjugados de expec |
| WO2019175145A1 (en) | 2018-03-12 | 2019-09-19 | Janssen Vaccines & Prevention B.V. | Vaccines against urinary tract infections |
| US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| IL286467B2 (en) | 2019-03-18 | 2026-02-01 | Janssen Pharmaceuticals Inc | Methods for producing bioconjugates of polysaccharides E. coli o-antigen, preparations thereof and methods for using them |
| EP3941516A1 (en) * | 2019-03-18 | 2022-01-26 | Janssen Pharmaceuticals, Inc. | Bioconjugates ofe col! o-antigen polysaccharides. methods of production thereof. andmethods of use thereof |
| MY209568A (en) | 2020-01-16 | 2025-07-22 | Janssen Pharmaceuticals Inc | Fimh mutant, compositions therewith and use thereof |
| MX2022010350A (es) * | 2020-02-23 | 2022-09-19 | Pfizer | Composiciones de esquerichia coli y sus metodos. |
| ES2984813T3 (es) | 2020-04-28 | 2024-10-31 | Janssen Pharmaceuticals Inc | Método para la identificación y la cuantificación de polisacáridos en composiciones de glicoconjugados complejas |
| BR112022023234A2 (pt) | 2020-06-25 | 2023-01-03 | Glaxosmithkline Biologicals Sa | Proteínas de exotoxina a modificada |
| AU2021342797B2 (en) * | 2020-09-17 | 2024-02-08 | Janssen Pharmaceuticals, Inc. | Multivalent vaccine compositions and uses thereof |
| US12138302B2 (en) | 2020-10-27 | 2024-11-12 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| CA3203450C (en) | 2020-11-30 | 2025-05-13 | Janssen Pharmaceuticals, Inc. | METHOD FOR ANALYSIS OF GLYCOCONJUGATES USING A CAPILLARY-BASED IMMUNOASSAY SYSTEM |
| US12357681B2 (en) | 2020-12-23 | 2025-07-15 | Pfizer Inc. | E. coli FimH mutants and uses thereof |
| JP7532672B2 (ja) | 2021-01-12 | 2024-08-13 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | ＦｉｍＨ変異体、それを含む組成物、及びその使用 |
| US20220236283A1 (en) * | 2021-01-28 | 2022-07-28 | Janssen Pharmaceuticals, Inc. | Method for identification and quantification of polysaccharides in complex glycoconjugate compositions |
| WO2022178020A1 (en) | 2021-02-16 | 2022-08-25 | Duke University | Vaccine compositions and methods for the treatment and prevention of urinary tract infections |
| KR20230164108A (ko) | 2021-04-01 | 2023-12-01 | 얀센 파마슈티칼즈, 인코포레이티드 | E. coli O18 생물접합체의 생산 |
| EP4281108A1 (en) | 2021-04-08 | 2023-11-29 | Janssen Pharmaceuticals, Inc. | Process for bioconjugate production |
| AR131046A1 (es) * | 2022-11-15 | 2025-02-12 | Janssen Pharmaceuticals Inc | Composiciones de vacunas multivalentes y sus usos |
| EP4478050A1 (en) | 2023-06-12 | 2024-12-18 | Janssen Pharmaceuticals, Inc. | Method for quantifying bound acetate in glycoconjugates |
| WO2025172892A1 (en) | 2024-02-16 | 2025-08-21 | Glaxosmithkline Biologicals Sa | Modified proteins and methods |
| CN118286407B (zh) * | 2024-04-08 | 2025-04-01 | 江西省农业科学院畜牧兽医研究所 | 一种禽大肠杆菌病三价灭活疫苗及其制备方法 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3700612A (en) | 1971-06-23 | 1972-10-24 | Tenneco Chem | Aqueous surface-coating compositions containing hydroxyalkyl ethers of galactomannan gums as thickeners |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422653D0 (en) | 1984-09-07 | 1984-10-10 | Technology Licence Co Ltd | Monoclonal antibodies |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| US5370872A (en) | 1991-08-12 | 1994-12-06 | Swiss Serum And Vaccine Institute Berne | Escherichia coliO-polysaccharide-protein conjugate vaccine |
| AUPM399594A0 (en) | 1994-02-21 | 1994-03-17 | Csl Limited | Antigenic preparation for treatment or prevention of helicobacter infection |
| US6858211B1 (en) | 1998-07-20 | 2005-02-22 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccines against Escherichia coli O157 infection |
| EP1278548A2 (en) | 2000-04-18 | 2003-01-29 | Endobiologics, Incorporated | Lipopolysaccharide-conjugate vaccine for sepsis treatment |
| RU2189253C1 (ru) | 2001-04-09 | 2002-09-20 | Государственный научный центр прикладной микробиологии | Диагностикум для идентификации escherichia coli o157 : h7 и способ его получения |
| US7117096B2 (en) | 2001-04-17 | 2006-10-03 | Abmaxis, Inc. | Structure-based selection and affinity maturation of antibody library |
| AU2003217912A1 (en) | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| PT1481057E (pt) | 2002-03-07 | 2006-05-31 | Eidgenoess Tech Hochschule | Sistema e metodo para a producao de proteinas glicosiladas recombinantes num hospedeiro procariota |
| AU2003901008A0 (en) | 2003-03-04 | 2003-03-20 | Anadis Ltd | Composition for the treatment and prevention of bacterial infections |
| CN1950397B (zh) | 2004-03-30 | 2012-05-16 | Ns基因公司 | 生长因子NsG33的治疗用途 |
| HUP0700044A2 (en) * | 2004-05-14 | 2009-03-30 | Ca Nat Research Council | Conserved inner core lipopolysaccharide epitopes as multi-species vaccine candidates |
| DE602006017207D1 (de) | 2005-05-11 | 2010-11-11 | Eth Zuerich | Rekombinante n-glykosylierte proteine aus prokaryontischen zellen |
| WO2007109813A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Imidazoquinoxaline compounds as immunomodulators |
| EP2007765B1 (en) | 2006-03-23 | 2012-06-27 | Novartis AG | Immunopotentiating compounds |
| JP4791866B2 (ja) | 2006-03-24 | 2011-10-12 | 国立大学法人秋田大学 | 下痢原性大腸菌感染症の判別に用いられる固相等 |
| EP3124497B1 (en) | 2007-09-14 | 2020-04-15 | Adimab, LLC | Rationally designed, synthetic antibody libraries and uses therefor |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| JP5647899B2 (ja) | 2008-01-08 | 2015-01-07 | ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ | オリゴサッカリルトランスフェラーゼを使用するポリペプチドの複合糖質化 |
| AU2009215341B2 (en) * | 2008-02-20 | 2015-03-26 | Glaxosmithkline Biologicals S.A. | Bioconjugates made from recombinant N-glycosylated proteins from procaryotic cells |
| EP3461840A1 (en) | 2009-04-27 | 2019-04-03 | Immuron Limited | Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of non alcoholic steatohepatitis |
| TR201803015T4 (tr) | 2009-11-19 | 2018-03-21 | Glaxosmithkline Biologicals Sa | Prokaryotik hücrelerde immünojenik polisakaridler üreten biyosentetik sistem. |
| KR102024922B1 (ko) | 2010-07-16 | 2019-09-25 | 아디맵 엘엘씨 | 항체 라이브러리 |
| CA2819366A1 (en) | 2010-12-10 | 2012-06-14 | Merck Sharp & Dohme Corp. | Novel formulations which mitigate agitation-induced aggregation of immunogenic compositions |
| JP2014526449A (ja) | 2011-09-06 | 2014-10-06 | グリコヴァキシン アーゲー | 原核細胞において製造されるバイオコンジュゲートワクチン |
| US9932598B2 (en) | 2012-08-02 | 2018-04-03 | The Regents Of The University Of California | Metabolic engineering of microbial organisms |
| AU2013311534A1 (en) * | 2012-09-10 | 2015-03-12 | Glycovaxyn Ag | Bioconjugates comprising modified antigens and uses thereof |
| ES2905107T3 (es) | 2012-10-12 | 2022-04-07 | Glaxosmithkline Biologicals Sa | Procedimientos de modificación de células hospedadoras |
| WO2014102265A1 (en) | 2012-12-27 | 2014-07-03 | Glycovaxyn Ag | Methods and compositions relating to crm197 |
| PT2945651T (pt) | 2013-01-17 | 2018-06-12 | Arsanis Biosciences Gmbh | Anticorpo específico para mdr e. coli |
| KR20160062169A (ko) | 2013-10-11 | 2016-06-01 | 글리코박신 아게 | 숙주 세포 변형 방법 |
| CA2935532A1 (en) | 2014-02-06 | 2015-08-13 | Arsanis Biosciences Gmbh | E. coli specific antibody sequences |
| AU2015220723C1 (en) | 2014-02-24 | 2018-04-05 | Glaxosmithkline Biologicals Sa | Novel polysaccharide and uses thereof |
| DK3240895T3 (da) | 2014-12-30 | 2022-04-11 | Glaxosmithkline Biologicals Sa | Sammensætninger og fremgangsmåder til proteinglykosylering |
| TWI715617B (zh) | 2015-08-24 | 2021-01-11 | 比利時商葛蘭素史密斯克藍生物品公司 | 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物 |
| AR109621A1 (es) | 2016-10-24 | 2018-12-26 | Janssen Pharmaceuticals Inc | Formulaciones de vacunas contra glucoconjugados de expec |
| GB201711635D0 (en) | 2017-07-19 | 2017-08-30 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| IL286467B2 (en) | 2019-03-18 | 2026-02-01 | Janssen Pharmaceuticals Inc | Methods for producing bioconjugates of polysaccharides E. coli o-antigen, preparations thereof and methods for using them |
| EP3941516A1 (en) | 2019-03-18 | 2022-01-26 | Janssen Pharmaceuticals, Inc. | Bioconjugates ofe col! o-antigen polysaccharides. methods of production thereof. andmethods of use thereof |
| FR3098334B1 (fr) | 2019-07-05 | 2021-07-23 | Airbus Operations Sas | Procédé et système de surveillance d’un état de conscience d’un opérateur dans un poste de pilotage d’un aéronef |
-
2016
- 2016-08-23 TW TW105126945A patent/TWI715617B/zh active
- 2016-08-24 MX MX2018002340A patent/MX2018002340A/es unknown
- 2016-08-24 EP EP23176994.4A patent/EP4245320A3/en active Pending
- 2016-08-24 KR KR1020187007898A patent/KR102735147B1/ko active Active
- 2016-08-24 PL PL16760616.9T patent/PL3341016T3/pl unknown
- 2016-08-24 AU AU2016312422A patent/AU2016312422B2/en active Active
- 2016-08-24 ES ES16760616T patent/ES2951408T3/es active Active
- 2016-08-24 EP EP16760616.9A patent/EP3341016B9/en active Active
- 2016-08-24 JP JP2018510886A patent/JP6872532B2/ja active Active
- 2016-08-24 CN CN201680062232.7A patent/CN108430500B/zh active Active
- 2016-08-24 RS RS20230664A patent/RS64449B1/sr unknown
- 2016-08-24 SM SM20230220T patent/SMT202300220T1/it unknown
- 2016-08-24 BR BR112018003469A patent/BR112018003469A2/pt not_active Application Discontinuation
- 2016-08-24 EA EA201890400A patent/EA037500B1/ru unknown
- 2016-08-24 HU HUE16760616A patent/HUE063961T2/hu unknown
- 2016-08-24 WO PCT/US2016/048278 patent/WO2017035181A1/en not_active Ceased
- 2016-08-24 US US15/754,867 patent/US10583185B2/en active Active
- 2016-08-24 HR HRP20230947TT patent/HRP20230947T1/hr unknown
-
2018
- 2018-02-19 IL IL257608A patent/IL257608B/en unknown
-
2020
- 2020-02-04 US US16/781,526 patent/US11484582B2/en active Active
-
2022
- 2022-09-23 US US17/934,781 patent/US12076385B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL257608A (en) | METHODS AND PREPARATIONS FOR IMMUNE PROTECTION FROM e. Pathogenic coli outside the intestines | |
| IL284076A (en) | Preparations containing bacterial strains | |
| IL272343A (en) | Preparations containing bacterial strains | |
| GB2596653B (en) | Compositions comprising bacterial strains | |
| GB2561749B (en) | Compositions comprising bacterial strains | |
| ZA201707745B (en) | Compositions comprising bacterial strains | |
| IL255757A (en) | Preparations containing bacterial strains | |
| SG10201912326QA (en) | Compositions comprising bacterial strains | |
| SMT201900665T1 (it) | Composizioni comprendenti ceppi batterici | |
| GB2561629B (en) | Methods, Compositions and uses relating thereto | |
| ZA201800694B (en) | Pathogen resistant citrus compositions, organisms, systems, and methods | |
| GB201520502D0 (en) | Compositions comprising bacterial strains | |
| GB201520628D0 (en) | Compositions comprising bacterial strains | |
| GB201520506D0 (en) | Compositions comprising bacterial strains | |
| GB201520508D0 (en) | Compositions comprising bacterial strains | |
| GB201520501D0 (en) | Compositions comprising bacterial strains | |
| GB201520510D0 (en) | Compositions comprising bacterial strains | |
| GB201510466D0 (en) | Compositions comprising bacterial strains | |
| GB201510468D0 (en) | Compositions comprising bacterial strains | |
| GB201510467D0 (en) | Compositions comprising bacterial strains | |
| GB201510470D0 (en) | Compositions comprising bacterial strains |